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Abstract: This article pioneers a study into the influence of the high-Z component of nanoparticles on 
the efficacy of radioprotection some nanoparticles offer to exposed cells irradiated with X-rays. We 
reveal a significant decrease in the radioprotection efficacy for cells exposed to CeO2 
nanoparticles and irradiated with 10 MV and 150 kVp X-rays. In addition, analysis of the 150 kVp 
survival curve data indicates a change in radiation quality, becoming more lethal for irradiated cells 
exposed to CeO2 nanoparticles. We attribute the change in efficacy to an increase in high linear energy 
transfer Auger electron production at 150 kVp which counterbalances the CeO2 nanoparticle 
radioprotection capability and locally changes the radiation quality. This study highlights an 
interesting phenomenon that must be considered if radiation protection drugs for use in radiotherapy 
are developed based on CeO2 nanoparticles. 
 
 
 
 
A counterbalance exists between radioprotection and enhancement for CeO2 NPs. The influence of 
this high-Z property is revealed on radioresistant 9L cells, where greater radioprotection was 
achieved using 10 MV photons in comparison to that achieved when using 150 kVp X-rays. At lower 
energies, high-LET Auger electron cascades create clustered, indirect and dominant direct damages 
and free radicals that are scavenged by CeO2 or recombine resulting in formation of H2O. Conversely, 
at higher energies, low-LET secondary electrons create dominantly free radicals that both: are 
scavenged by CeO2 NPs and can indirectly damage DNA. This unique mechanism should be 
considered throughout all nanoparticle based radiotherapy where high-Z nanoparticles such as CeO2 
are used. 
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Abstract
This article pioneers a study into the influence of the high-Z component of nanoparticles
on the efficacy of radioprotection some nanoparticles offer to exposed cells irradiated with X-
rays. We reveal a significant decrease in the radioprotection efficacy for cells exposed to CeO2
nanoparticles and irradiated with 10 MV and 150 kVp X-rays. In addition, analysis of the
150 kVp survival curve data indicates a change in radiation quality, becoming more lethal for
irradiated cells exposed to CeO2 nanoparticles. We attribute the change in efficacy to an increase
in high linear energy transfer Auger electron production at 150 kVp which counterbalances the
CeO2 nanoparticle radioprotection capability and locally changes the radiation quality. This
study highlights an interesting phenomenon that must be considered if radiation protection
drugs for use in radiotherapy are developed based on CeO2 nanoparticles.
Keywords: Cerium oxide nanoparticles, High-Z, Radioprotectors, Photoelectric effect, Ra-
dioresistant
The application of nanotechnology to medicine provides an innovative approach that can1
enhance the effectiveness of radiotherapy1. Targeted and non-targeted tissues and cells are,2
in general, damaged along an indirect pathway during radiation treatment as a result of the3
production of free radicals2. Free radical production can result in chemical reactions that damage4
DNA molecules and initiates apopotosis and mitotic death3,4. The protective mechanisms of a5
cell in response to ionizing radiation exposure are insufficient and have prompted the research and6
development of novel nanoparticles (NPs) with the ability to enhance or assist cell protective7
mechanisms. If such NPs act preferentially and protect normal tissues that surround target8
tissues it would allow dose escalation to the target for better tumour control and hence improved9
patient outcomes.10
One novel nanoparticle currently under investigation for its ability to provide protection against11
2
radiation induced damage is cerium oxide (CeO2)
5. Previous studies investigated the free-radical12
scavenging effectiveness of CeO2 NPs to provide radioprotection in vitro for a variety of normal13
cell lines, and in vivo with athymic nude mice6,7. CeO2 NPs inherit an autoregenerative cycle14
(Ce3+– Ce4+– Ce3+) that enables continued antioxidant activity, providing long-term scavenging15
of reactive oxygen species (ROS)8. CeO2 NPs now offer a prospective alternative to the only16
clinically used radioprotector — amifostine9. Amifostine has the limitation of considerable side17
effects, a short half-life in serum and high cost caused by frequent dosing requirements3.18
Many avenues need to be explored prior to the clinical acceptance of CeO2 NPs and its application19
as a radioprotector. Current investigations using CeO2 NPs explore characteristics such as:20
its bioavailability/toxicity10–12, the ability to provide radiation protection by scavenging free21
radicals and the selective nature of its protection to normal and cancerous cells7. However, steps22
towards the clinical acceptance of CeO2 NPs requires an understanding of its effectiveness across23
a range of beam energies. To the best of our knowledge, the influence of the above effects have24
never been reported in the literature.25
X-rays used throughout clinical treatments produce free radicals through interactions with mat-26
ter2. Interactions of interest include — photoelectric and Compton effects, coherent scattering27
along with pair production at higher energies. The most influential factors dictating the cross-28
section for these interactions is the radiation energy (E) and atomic number (Z). The mass29
attenuation coefficient due to the photoelectric effect is approximately proportional to (Z/E)3,30
where Z is the atomic number of the absorbing medium and E is the photon energy13. The use of31
high-Z nanoparticles (i.e. gold NPs, ZAu = 79) in dose enhancement provides an example of how32
we can exploit the dependence of the photoelectric effect13–15. The majority of Auger electrons33
are produced as a consequence of the photoelectric effect supporting the notion that their34
greatest abundance is achieved when the cross-section for the photoelectric effect is maximised.35
Compton interactions occur with outer shell electrons and subsequently, have no significant Z36
dependence16. A threshold photon energy of 1.022 MeV exists for pair production, with a cross37
section that increases rapidly with energy above the threshold13. Furthermore, pair production38
cross-section has a quadratic proportionality with Z. The linear energy transfer (LET) is a39
measure of the energy locally imparted to a medium by a secondary charged particle of energy40
(E) along its path2,16. The variation of the LET with decreasing electron energy is an important41
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consideration in our study as increases in LET correspond to increases in the relative biological42
effectiveness (RBE) of the radiation field17. Auger electrons have a LET that lies in the range of43
10 - 25 keV/µm18 while the positron-electron pair produced during the pair production process44
with kinetic energy of a few MeV have a LET of 0.2 keV/µm17. Ultimately, Auger electrons45
deposit their energy along their tracks in a very short range, indicating an increase in the46
biological effectiveness of radiation exposure at lower energies13. CeO2 is a known radioprotector47
however, the high-Z (ZCe = 58) component of this material is the major contributor towards48
potential increases in the RBE.49
In this article, we postulate that CeO2 NPs efficacy to function as a radioprotector is dependent50
on the energy of X-rays used during treatment and we investigated this energy-dependence using51
150 kVp X-ray and 10 MV photon beams. Furthermore, to prove the existence of any high-Z52
enhancement abilities that CeO2 may possess, we select the radioresistant 9L cell line.53
Cell survival curves are an effective analytical method that we utilise to measure the effectiveness54
of CeO2 NPs to provide radioprotection. Radiobiological properties such as radiosensitivity and55
repair accumulation can be extracted using this analysis, where the influence on these parameters56
by the CeO2 NP are determined for the first time.57
Our study reveals an energy-dependent efficacy due to the influence of the high-Z component58
of CeO2 NPs (Zeff = 54). At 10 MV, indirect damage effects dominate and mainly results59
from the interaction of molecules contained in cells and the free radicals produced during the60
radiolysis of water. The radioprotection provided by CeO2 NPs is achieved using free-radical61
scavenging effects, facilitating increased repair while lowering the cells radiosensitivity. At lower62
X-ray beam energies, the probability of direct damage effects become an increasingly important63
consideration and are no longer negligible17. Low energy secondary electrons have an increased64
probability to produce clusters of free radicals that can provoke the rupture of covalent bonds65
and scissions in the molecules contained within cells17. The additional presence of free radicals66
cannot be fully managed by the scavenging abilities of CeO2, adding further weight to increased67
damaging effects at lower energies. The work described in this article reveals that the free-radical68
scavenging effect is counterbalanced by the high-Z atoms present in the elemental composition69
of CeO2. These high-Z atoms are responsible for an increased production of lethally damaging,70
low energy secondary electrons.71
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Methods72
Cell line73
The rat brain gliosarcoma cell line (9L) was obtained from the European Collection of Cell74
Cultures (ECACC). Derived from a N-nitrosomethylurea-induced tumour, this adherent radiore-75
sistant cell line inherits glial morphology and has undergone routine mycoplasma contamination76
testing.77
Cell culture78
The 9L gliosarcoma cells were grown and maintained during their exponential growth phase79
in T75 cm2 BD FalconTM tissue culture flasks (Franklin Lakes, NJ, USA) containing Dulbecco’s80
Modified Eagle Medium (DMEM) with L-Glutamine, supplemented with 10% (v/v) Fetal Bovine81
Serum (FBS) and 1% (v/v) Penicillin/Streptomycin (PenStrep). Cell cultures were passaged82
upon reaching 85% confluence to a concentration of 2–4 × 104 cells/cm2 and stored at 37◦C in83
a 5% (v/v) CO2 cell culture incubator. In our hands, the cell doubling time was deduced to84
be 36 h. All chemical reagents used were purchased from GIBCO R©, unless indicated otherwise.85
All cell culture work was carried out at the Illawarra Health and Medical Research Institute86
(Wollongong, NSW, Australia).87
Nanoparticle synthesis and preparation88
The cerium oxide nanoparticle sample was synthesised at the Institute for Superconducting89
and Electronic Materials (Wollongong, NSW, Australia) using a spray pyrolysis technique19,20.90
This synthesis approach produces compounds of high purity and chemical homogeneity, yielding91
a nanoparticle with reproducible size and characteristics. A 1 L aqueous solution was prepared,92
consisting of 0.45 mol/L of Ce(NO3)3 and 6H2O. This solution was sprayed and decomposed at93
500◦C using a customised spray pyrolysis system designed for the engineering of nanoceramics94
and composites. Cerium oxide NP samples were dried prior to sterilisation using an open furnace95
operating at 140◦C for a period no less than 2 h. Sterilisation was achieved using an autoclave96
operating at 121◦C on a dry cycle, with sterilised samples kept in glass vials surrounded by silica97
gel to avoid moisture absorption. Cerium oxide NPs were dispersed in Dulbecco’s Phosphate-98
Buffered Saline (DPBS) to solubilise the NP. Sonication and vortex mixing was used to minimise99
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the size of NP aggregates and increase the homogeneity of dispersion prior to exposure. A100
concentration of 50 µg/ml was applied to 9L cells for subsequent analysis.101
X-ray Diffraction102
A slurry of nanoparticle was produced via vigorous mixing with 100 % ethanol which was103
placed onto a quartz sample holder. The sample was presented to the monochromatic, copper Kα104
X-ray beam (λ = 1.5406 Å). The X-ray diffraction analysis was performed using an automated105
GBC R© eMMA X-ray Diffractometer (GBC, VIC, Australia) where the sample was scanned using106
a step size of 0.2◦ 2θ through the range of 20◦ - 70◦ 2θ with a count time of 8.75 seconds per107
step. The operational settings used were 25 mA and 40 kVp. Phase identification was extracted108
by comparing the recorded diffraction pattern with the Inorganic Crystal Structure Database109
(ICSD). The average nanoparticle crystallite size (Tc) is extracted from the X-ray diffraction110
data using Scherrer’s equation (1).111
Tc =
Kλ
βcos(θB)
(1)
K is the shape factor constant (K = 0.89), λ is the X-ray beam wavelength, β is the FWHM112
(in radians) and θB is the Bragg angle.113
Transmission Electron Microscopy114
Transmission electron microscopy (TEM) was performed using a JEOL 2011 high resolution115
(HR) instrument, characterising the size and morphology of the sample. The samples were116
prepared by dispersion of CeO2 powders onto holey carbon support films.117
Gas sorption analysis118
The specific surface area of the powder samples was measured by the Brunauer-Emmett-119
Teller (BET) method with a Nova 1000 high speed gas sorption analyser from Quantachrome,120
using the adsorption of N2 at the temperature of liquid nitrogen. Prior to measuring, the samples121
were degassed at 120◦C for 2 h 30 min in vacuum.122
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Irradiation of cell culture123
All irradiations were performed in the radiation oncology department at the Prince of Wales124
Hospital (Randwick, NSW, Australia). The confluent cell culture was irradiated following a125
24 h incubation period with cerium oxide nanoparticles at a concentration of 50 µg/ml. Prior126
to megavoltage irradiation, non-vented T12.5 cm2 tissue culture flasks (BD FalconTM) were127
completely filled with Hank’s Balanced Salt Solution (HBSS) to ensure no air bubbles were128
present inside the flask, maximising the accuracy of the dose delivered at the depth of the cells.129
Kilovoltage irradiation was performed using only a 6 mm depth of medium in an attempt to130
maximise the accuracy of the dose delivered to the cell monolayer. Beam energies of 10 MV131
and 150 kVp were explored using an Elekta AxesseTM LINAC (Elekta AB, Kungstensgatan,132
Stockholm, Sweden) and a Nucletron Oldelft Therapax DXT 300 Series 3 Orthovoltage unit133
(Nucletron B.V., Veenendaal, The Netherlands), respectively. All doses (1, 2, 3, 5 & 8 Gy)134
were delivered in single fractions at room temperature. Tissue culture flasks were irradiated in135
a horizontal orientation with solid water placed both underneath and around the sides of the136
flasks, primarily to maintain adequate backscattering effects and stabilise electronic equilibrium.137
Unirradiated control samples (with and without CeO2 NPs) were utilised and handled under the138
same conditions as the irradiated samples.139
Clonogenic cell survival assay140
Cell survival was assessed using a clonogenic cell survival assay, otherwise known as a colony-141
forming assay21,22. Adherent cell lines, such as 9L, have the ability to form colonies in vitro even142
at low density cell seeding. Following radiation exposure, all of the flasks were promptly plated,143
initiating the clonogenic assay (duration of 15 doubling times for 9L cells). The growth media was144
removed and the confluent cell culture was thoroughly washed with DPBS containing no calcium145
(Ca) or magnesium (Mg) salts. The cells were then detached from the surface of the flask with a 2-146
3 minute incubation with 0.05% trypsin ethylenediaminetetraactic acid (Trypsin-EDTA), forming147
a cell suspension that was counted using a haemocytometer. Cells were seeded at low densities in148
triplicate into 100 mm Sigma-Aldrich R© petri dishes containing 10 ml of the DMEM. All plates149
were incubated at 37◦C and 5% CO2 for 15 cell doubling times. Each prescribed dose used a150
maximum of three different cell seeding numbers, all determined by preliminary experiments to151
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narrow the optimal seeding to achieve an approximate number of colonies of 100. Following the152
incubation period, formed colonies were fixed and stained using a solution comprised of 75%153
(v/v) ethanol and 25% (v/v) crystal violet (Sigma-Aldrich R©). Colonies containing 50 cells or154
more, confirmed by the use of a high powered inverted microscope are counted for analysis.155
Cell survival data is presented using the relative surviving fraction of cells as a function of156
absorbed dose. The surviving fraction is extracted from the plating efficiency. The Plating157
Efficiency (PE) is calculated as the ratio of viable colonies to cells seeded.158
PE =
No. of colonies counted
No. of cells seeded
(2)
The Surviving Fraction (SF) was determined by comparing the PE at a given dose to the159
control (i.e. no dose). The surviving fraction is given by:160
SF (D) =
PE(D)
PE(0)
(3)
where SF(D) and PE(D) is the surviving fraction and plating efficiency at dose D (Gy),161
respectively.162
PE(0) is the plating efficiency of unirradiated controls (0 Gy) with or without NPs used for163
normalisation of irradiated samples with or without NPs, respectively. The plating efficiencies164
given are the mean PE values from duplicate samples at each dose.165
166
Statistical analysis167
Cell survival experiments were replicated once and measured in triplicate on each occasion.168
The reported values are the mean of all experiments, with the experimental uncertainty given169
as one standard deviation. The LQ model was fitted to cell survival data using KaleidaGraph170
software. The fit of the data is weighted by the reported error at each dose in the determination of171
the radiobiological constants of the LQ model. Statistical analysis of toxicity data was performed172
using a two-tailed Student’s t -test using the assumption of equal variance. A P value of ≤ 0.05173
was considered statistically significant.174
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Cell survival analysis175
The cell survival curves are constructed on a semi-logarithmic plot of the surviving fraction176
as a function of absorbed dose. The cell survival curve can be represented mathematically using177
the linear quadratic (LQ) model as X-ray (i.e. low LET) radiation sources are used2,23.178
SF (D) = exp(−αD − βD2) (4)
The parameters α (Gy−1) and β (Gy−2) are measures of the radiosensitivity and repair179
accumulation, respectively. The surviving fraction data was fitted to the LQ model using180
KaleidaGraph software, extracting the α and β constants for each set of cell survival data.181
Protection enhancement ratio182
The Protection Enhancement Ratio (PER) is a value used to measure the degree of protection183
achieved using CeO2 NPs. The PER can be defined as the ratio of doses in the presence of CeO2184
to the control (i.e. no NP), as measured at the common endpoint of 10 % cell survival.185
PERSF=10% =
DoseCeO2
Dosecontrol
(5)
A PER value greater than 1 is indicative of radioprotection, whereas a PER value less than 1186
reveals a sensitisation effect. This effect is manifested as a direct result of the presence of CeO2187
NPs.188
Results189
Phase and structural characterisation of cerium oxide190
The biochemical effect of nanoparticles are dependent on their structural and physical char-191
acteristics. Characteristics of particular interest include: phase composition, structure and192
crystallite size. First order diffraction peaks have been labelled (Figure 1, A) upon correlating193
recorded data against the ICSD (PDF card no. 01-089-8436). Cerium oxide nanoparticle’s phase194
is confirmed to exist as CeO2. This matches the phase of the cerium oxide NPs that have been195
reported to provide protection in response to exposure of ionising radiation3,5–7. Using the XRD196
9
data, the structure of the sample can be extracted. The CeO2 NP sample has a simple cubic197
crystalline structure with a single lattice parameter, a = 5.4112 Å. The average crystallite size198
can be extracted from the XRD peaks using Scherrer’s equation. The most accurate analysis199
is achieved by selecting the most pronounced peaks, free of any contribution from surrounding200
satellite peaks. The average crystallite size was calculated to lie in the range of 6–8 nm, consistent201
with the crystallite sizes observed in the HR-TEM image (Figure 1, B). The high resolution202
transmission electron micrograph (HR-TEM) shows clear lattice fringes (Figure 1, B) with a203
fringe spacing (d) of 3.15 Å, which corresponds to the distance between the 111 lattice planes of204
CeO2. The calculated BET specific surface area of the nanocrystalline powder was 51 m
2/g.205
Toxicity of CeO2 NPs to 9L cells206
No definitive conclusions have been made regarding the toxicity of CeO2 NPs
3,6,7,24. Efforts207
to determine its biological viability remains the subject of numerous studies and is an integral208
component to the development of any model using CeO2
8,10,11,24–27. Initially, we investigated the209
toxicity of our synthesised CeO2 NP to 9L cells. The clonogenic cell survival assay was conducted210
following a 24 h incubation with CeO2 NPs at a range of concentrations up to 500 µg/ml. We211
established that the application of CeO2 NPs had no statistically significant toxic effect on the212
surviving fraction of 9L cells at 50 µg/ml (Figure 2) where we found a surviving fraction of213
0.93 ± 0.07 (P value: 0.2, CeO2 vs no NP control). The toxicity of CeO2 NPs is found to214
be concentration dependent and this effect should be considered when implementing CeO2 as a215
radioprotector.216
Efficacy of CeO2 NPs when used in synergy with different X-ray beams217
The gliosarcoma cell line, 9L, was exposed to CeO2 NPs at a concentration of 50 µg/ml during218
a 24 h incubation period prior to irradiation. The control flasks were incubated in the absence219
of the NP. All conditions remained constant besides the presence and absence of the NP. The220
first X-ray beam used was a 150 kVp beam and was chosen for both, its clinical relevance and to221
maximise the dose enhancement to the CeO2 doped medium to a water equivalent medium based222
on the formalism described by Corde et al. 28 The 150 kVp beam produces an effective energy223
of 65 keV which lies close to, yet above the energy required to maximise dose enhancement (i.e.224
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54 keV). The cells were exposed to a range of doses up to 8 Gy. The samples were irradiated225
using either a 150 kVp or 10 MV X-ray beam to probe the effectiveness of CeO2 NPs across a226
range of beam energies. Cell survival curves were produced using the clonogenic cell survival227
assay. This technique enabled any effect caused by the presence of the NP to be observed and228
quantified. The results show that the 9L cell line has a response that varies with treatment229
beam energy (Figure 3). The radiobiological parameters (α, β) for 9L cells are investigated for230
different radiation sources in the presence and absence of CeO2 NPs. It is evident that CeO2231
NPs exhibit a protective effect to 9L cells when irradiated using a 10 MV photon beam (Figure232
3, A). A higher surviving fraction at all doses was observed in the presence of CeO2 NPs relative233
to the control sample. The radiosensitivity of 9L cells decreases in the presence of CeO2 NPs234
with a corresponding increase in the damage repair as portrayed throughout table 1. A PER235
value of 1.23 ± 0.003 is achieved during the 10 MV treatment, confirming the radioprotective236
ability of CeO2 NPs. A contrary effect is observed in response to exposure from the 150 kVp237
X-ray beam (Figure 3, B), where the surviving fraction in the presence of CeO2 NPs is similar238
to the 9L control sample, revealing the consequence of the high-Z component of CeO2 NPs. We239
observe a minor increase in radiosensitivity of 9L cells in the presence of CeO2 coupled with240
the lack of evidence of damage repair, which is confirmed from the linear trend of the survival241
curve (Table 1). Subsequently, a PER close to unity is deduced, suggesting that CeO2 NPs242
possess an energy-dependent radioprotection efficacy. We believe that a counterbalance between243
the sensitisation effect caused by increases in the RBE at lower photon energies15,29 and the244
radioprotection offered through CeO2’s free-radical scavenging ability
6 is responsible for these245
energy-dependent effects.246
Discussion247
The application of CeO2 NPs to clinical radiation protection is the subject of numerous248
studies and development3,5–7. Nanomedicine is a vastly expanding and alternative approach to249
existing medicines with applications ranging from diagnostic imaging and therapeutic radiation250
enhancement to radiation protection6,15,30. Minimising radiation-induced side effects is the focus251
of many studies and the catalyst in the production and development of novel approaches to252
radiation protection28,31. Scavenging free radicals is the most common approach used to provide253
11
radiation protection. Development of new and improved radioprotectors as an alternative to254
amifostine is of great importance as a result of its clinical limitations3,9.255
We synthesised CeO2 NPs using spray pyrolysis techniques for their application in radiation256
protection. High nanoparticle yield and reproducible characteristics such as size, phase and257
crystallinity are key advantages provided by our synthesising approach over alternative techniques258
of nanoparticle production32. Characterisation of our synthesised sample using XRD revealed259
important properties that were essential for our application. Results show that we have a260
nanoparticle sample with a single cubic phase, existing as CeO2 upon comparison with the261
ICSD. The broad diffraction peaks (Figure 1) confirm the nano-crystallinity of CeO2, with262
the mean crystallite size measured to range from 6–8 nm. Tarnuzzer et al. 7 report parallel263
findings with their XRD analysis of CeO2, enabling us to suggest that our synthesised sample264
also exhibits these autoregenerative antioxidant effects for radiation protection. The HR-TEM265
image of CeO2 shows crystallite sizes that correlate with that determined in our X-ray diffraction266
analysis. Distinct lattice fringes are observed, supporting the presence of a cubic structure with267
the distance between successive fringes deduced to be 3.15 Å, consistent with our diffraction data268
and the PDF card no. 01-089-8436 as published in the ICS database. Light micrographs of 9L269
cells incubated with CeO2 NPs show that they are randomly distributed, i.e. around, on and270
alternately in the cells. However at such magnification, it is not possible to visualise intracellular271
localisation. Using flow cytometric analysis we deduce that CeO2 NPs can be internalised in 9L272
cells. The internalisation is confirmed as a result of increases in the measured cell side scatter273
(data not shown), a technique utilised by Busch et al. 33 Results of the gas sorption analysis show274
a nanocrystalline surface area of 51 m2/g, supporting the nanoscale crystallite size recorded. It275
is well known that the size of a nanoparticle is related its surface area, where smaller particles276
have greater surface areas11. Increasing the surface area could therefore act to maximise any277
related free-radical scavenging properties of CeO2 NPs.278
The toxicity of CeO2 NPs to 9L cells was tested to elucidate its clonogenic survival at concen-279
trations up to 500 µg/ml. We utilised mimetic experimental conditions to that used in radiation280
exposures, maximising the validity of the reported outcomes. Following a 24 h incubation of281
9L cells with CeO2 NPs, we report insignificant toxic effects at 50 µg/ml, consistent with other282
published literature6,7,27. Inconsistent conclusions have been made in regard to the toxic effects283
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of CeO2 NPs, a factor requiring further development
26. It is well documented that the size284
and structure of nanoparticles, influenced by the production process, dictate their toxicity6,26.285
Additional factors which should be investigated include: oxygen non-stoichiometry and balance286
of Ce3+/Ce4+ cation states, exposure time, concentration and aggregation of the nanoparticle,287
and also cell type as different toxic responses may occur10.288
It has been well established that CeO2 NPs utilise a unique free-radical scavenging ability to289
provide radioprotection in both cell culture and murine models. Important factors influencing290
the effectiveness of CeO2 include: cell sensitivity, NP concentration and synthesis and these291
factors should be further developed and understood in steps toward clinical acceptance.292
Figure 3A clearly indicates that the CeO2 NPs provide protection against radiation induced293
damage to gliosarcoma (9L) cells. Cell survival curves provide a wealth of information — not294
only a comparison of the response of cells exposed to radiation in the presence and absence295
of CeO2, but the influence of CeO2 on the radiobiological parameters, α and β used in the LQ296
model. Using a 10 MV photon beam, we record radioprotection at all doses up to 8 Gy with CeO2297
NPs at a concentration of 50 µg/ml. This radioprotection is supported by the increase in damage298
repair (β) and decrease in radiosensitivity (α) under the LQ model data interpretation observed299
in the presence of CeO2 NPs. While statistically there is no significant difference between the300
two survival curves at 150 kVp, analysis of the data under the LQ model indicates an increased301
linearity of the survival curve in the presence of the NP. Investigation of the radiobiological302
parameters within the LQ model shows a small increase in the radiosensitivity when CeO2 NPs303
are present. Within the LQ model the increased linearisation is interpreted as a change in the304
radiation spectrum. Therefore the increased linearity of the logarithmic cell survival suggests305
that CeO2 NPs enable more direct damage effects to occur due to the additional enhancement306
in the field of low energy electrons.307
The observed energy dependence of the PER efficacy (for 10 MV and 150 kVp) can be explained308
as a counterbalance between the free-radical scavenging ability of CeO2 and the increased RBE309
due to lower energy radiations. The increase in the RBE is, in part, influenced by the macroscopic310
dose enhancement from the mass-energy absorption of CeO2 and the increased yield of Auger311
electrons29,34,35. This energy dependence is also influenced by the increased production of photo-312
electrons, with a cross-section that is inversely proportional with energy (Figure 4). Photoelectric313
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interactions are important to consider for compounds such as CeO2 as the effective atomic314
number (Zeff=54)
36 has a strong influence on the photoelectric cross-section13. Photoelectric315
interactions stimulate two main processes – the ejection of characteristic X-rays and Auger316
electron cascades37,38. Auger electrons increase the average LET of the resultant secondary317
particles maximising the efficiency of these radiations through denser ionisations, imparting318
more direct damage which in turn reduces the abundance of reactive oxygen species responsible319
for indirect damage17. The 150 kVp X-rays yield a greater proportion of these higher LET320
particles than the 10 MV photon beam in the presence of CeO2 NPs, supporting the energy321
dependent efficacy of radioprotection that we observe. Ideally, a radioprotective compound322
would have a low atomic number to minimise effects such as energy dependent protection. The323
use of low-Z radioprotectors is supported by the current “gold standard” clinical radioprotector,324
amifostine, which has a low effective atomic number (Zeff=11). As radioprotectors generally325
function along a chemical pathway, the cross-section for the production of secondary particles326
should be minimised. The effect of the atomic number on the total photon interaction cross-327
section supports the notion that idealistic radioprotectors should have a low atomic number in328
order to be less dependent of the X-ray field energy spectra (Figure 4, B).329
In conclusion we have demonstrated that the radioprotection (via free-radical scavenging) efficacy330
of the CeO2 nanoparticle depends on the spectra of X-ray radiation. Our hypothesis is that331
the change in efficacy is driven by the high-Z component of CeO2 that leads to a modifica-332
tion of the electron spectra in close proximity to the nanoparticles that can counterbalance333
the radioprotection efficacy of CeO2. The electron spectra is modified through the increased334
production of low energy secondary electrons (including Auger cascades) that are generated335
due to predominance of the photoelectric effect at kilovoltage X-ray energies. The influence336
of these low energy electrons, with high LET, is reflected in the change of the shape of the337
survival curve for 9L cells exposed to CeO2 nanoparticles and irradiated with 150 kVp X-rays338
compared to 10 MV X-rays, which adds weight to our hypothesis. Therefore we have highlighted339
a very interesting phenomenon that must be considered if radiation protection drugs for use in340
radiotherapy are developed based on the CeO2 nanoparticle. This is particularly important in the341
case of cancer treatment delivered by different photon fields (e.g. superficial cancer treatment342
with 100 - 150 kVp photons in comparison with external beam radiotherapy delivered by 6-343
14
18 MV photons) where we have shown that the changes in the free-radical scavenging efficacy of344
CeO2 nanoparticles are pronounced. The scientific interest in the development of CeO2 NPs as a345
radioprotecting agent is evident throughout the widespread literature that contains both, in-vitro346
and in-vivo models3,5–8,10,24–27. Expanding our knowledge in the application and functionality347
of CeO2 NPs will continue with the long term goal of clinical implementation.348
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Figure 1: X-ray diffraction spectrum of the CeO2 NP sample synthesised by spray pyrolysis (A). Data was
acquired using an automated GBCR© eMMA X-ray Diffractometer. X-ray diffraction peaks were assigned Miller
indicies in correlation with the ICSD. High Resolution Transmission Electron Microscopy image of CeO2 NPs
synthesised using spray pyrolysis techniques (B).
Figure 2: The surviving fraction of 9L cells exposed to CeO2 NPs during a 24 h exposure at increasing
concentrations up to 500 µg/ml. The toxicity was measured using the clonogenic cell survival assay. Surviving
fraction data is presented with uncertainties given as one standard deviation with statistical significance measured
with a P value ≤ 0.05.
Figure 3: 9L clonogenic cell survival after irradiation with 10 MV (A) or 150 kVp (B) X-ray beams in the
presence (triangle) and absence (square) of CeO2 NPs at a concentration of 50 µg/ml. All uncertainties are
presented with one standard deviation made from duplicate samples which are measured in triplicate.
Figure 4: Energy dependence of the mass-energy absorption coefficients for the three main radiation interactions
are highlighted as a function of treatment beam energy for CeO2 (A). The total mass-energy absorption coefficients
for amifostine and CeO2 are shown over a range of energies (B) highlighting the influence on the mass-energy
absorption coefficient through increases in atomic number.
Table 1: Summary of the radiobiological parameters for 9L cells exposed to different radiation sources in the
presence and absence of CeO2 NPs. The LQ model was used to fit the surviving fraction data in KaleidaGraph,
extracting the α and β constants. All uncertainties listed are given as one standard deviation.
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Experimental Parameters 
 Control 50 μg/ml 
Radiation source α (Gy-1) β (Gy-2) α (Gy-1) β (Gy-2) 
150 kVp X-rays 0.21 ± 0.03 0.009 ± 0.004 0.30 ± 0.04 -- 
10 MV X-rays 0.20 ± 0.06 0.013 ± 0.008 0.06 ± 0.04 0.019 ± 0.005 
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